Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.71 |
| ▸ | SLC6A9 | P48067 | 10/20 | 0.70 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.68 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834651 | 1.00 | SLC18A3 (0.71) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL7706385 | 0.99 | SLC18A3 (0.69) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL7706383 | 0.99 | SLC18A3 (0.69) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL7706308 | 0.90 | SLC18A3 (0.69) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL7706310 | 0.90 | SLC18A3 (0.69) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL8049905 | 0.90 | SLC18A3 (0.72) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL7709383 | 0.89 | SLC18A3 (0.71) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL7709380 | 0.89 | SLC18A3 (0.71) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL7701388 | 0.89 | SLC6A9 (0.64) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL7701391 | 0.85 | SLC6A9 (0.65) | SLC18A3SLC6A9SLC6A5OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0921125-B1 | 1,3,8-Triazaspiro[4,5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | claimed |
| EP-0921125-A1 | 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | claimed |
| US-20040067950-A1 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING-PLOUGH CORPORATION | 2004-04-08 | — | — | US | disclosed |
| EP-0921125-B1 | 1,3,8-Triazaspiro[4,5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | disclosed |
| US-6043366-A | USEFUL IN TREATING DISORDERS INVOLVING THE ORPHANIN FQ(A SEVENTEEN AMINO ACID LONG PEPTIDE) RECEPTOR. | HOFFMAN-LA ROCHE INC. (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0921125-A1 | 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067950-A1 | High affinity ligands for nociceptin receptor ORL-1 | OPRL1, OPRD1, OGFRL1 | SLC18A3 1514/4885SLC6A9 2312/4885SLC6A5 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.